SMT (Sahajanand Medical Technologies Pvt. Ltd.), manufacturer of cardiovascular medical stents, announced the successful results of S flex UK Registry. The one-year outcome data of the study was presented at The British Cardiovascular Intervention Society (BCIS), 2018 held at London, UK. The outcome clearly demonstrated the safety and clinical performance of Supraflex, Sirolimus-Eluting Coronary Stent System thereby setting a new benchmark in Indian cardiovascular industry, which is ready to compete with global players.
Titled as Prospective Evaluation of the Supraflex, Sirolimus-Eluting Coronary Stent System in a 'Real-World' Patient Population, the S Flex UK Registry trial was conducted among 469 patients from July 2015 to November 2016. The study was conducted at 11 hospitals in the UK. The Primary endpoints of the study were Target Lesion Failure (TLF) at 12 months (Cardiac death, target vessel MI, or clinically-driven TLR). This real world, all comers, multi-centre UK registry of 469 patients undergoing PCI showed that the Supraflex stent to be safe with a TLF rate of 3.2% with no definite stent thrombosis, potential plus probable stent thrombosis incidence of 0.9% at 360 days.
The principal investigator of the study Dr. Azfar Zaman, professor of Cardiology, Freeman Hospital and Newcastle University, UK said, “The One-year safety and efficacy outcomes clearly highlight the excellent safety profile and excellent deliverability of Supraflex which is essential for PCI procedures. We believe ultrathin 60-micron struts, bio-degradable polymer and proven antiproliferative drug are the intrinsic elements to superior performance of Supraflex.”
“We are pleased to be able to report these excellent one-year results, confirming that Supraflex can be considered the new benchmark for DES, beginning of a new era of Ultrathin stents. We are committed to nurture the meaningful innovations that deliver better patient outcomes. Here we leverage a decade long healing experience while bringing the best of efficacy and safety outcomes offered through SMT DES.” added Cheran Uthirapathi, VP International sales & marketing, SMT.
Ecstatic about the successful results of S flex UK Registry Piyush Savalia, sr. v.p. marketing & clinical trial, SMT said, “Evidence Based Medicine is at the core of SMT’s product development strategy. Given the consistency with which the Supraflex stent has performed across the wide spectrum of clinical parameters through various other clinical studies, we are upbeat that UK S Flex study has produced positive and excellent clinical outcomes that physicians expect from a next generation DES”
The CE-approved Supraflex, new biodegradable polymer-coated sirolimus-eluting stent (SES) is designed using an ultrathin (60µm) cobalt–chromium (Co–Cr) stent platform with a highly flexible ‘S-link’, which would enhance the deliverability of the stent, particularly in complex and challenging lesions. Clinical trial programme on Supra family of products has covered more than 12000 patients across the world till date.
SMT (Sahajanand Medical Technologies) a leading medical devices company specializing in the provision of life-changing vascular solutions. SMT offers an extensive portfolio of products that set industry benchmarks in vascular intervention by being the 1st company in the world to receive CE approval for DES with biodegradable polymer. Other distinguished ‘benefactio’ includeultrathin (60µm) lowest strut thickness for all the DES options offered by the company. Company has global presence with its footprints in more than 60 countries.
Smt announces positive results, s flex uk registry
8.png)
